financetom
Business
financetom
/
Business
/
Thames Water creditors see a 'short and closing window' to rescue company
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Thames Water creditors see a 'short and closing window' to rescue company
Jun 4, 2025 6:44 AM

LONDON, June 4 (Reuters) - Thames Water's senior

creditors said there was a "short and closing window" for a

market-led rescue of the water company after U.S. private equity

firm KKR pulled out of a multi-billion pound funding

plan on Tuesday.

The creditors said on Wednesday they had submitted a

long-term plan to fix the root causes of Thames Waters'

problems.

The heavily indebted water company, Britain's biggest, moved

a step closer to nationalisation on Tuesday when KKR walked away

from investing about 4 billion pounds ($5.4 billion) of equity.

The group of senior debt holders said they had a proven

track record of stewardship and could deliver "substantial fresh

investment" to turn around the company under new leadership.

"The Creditors believe that Thames Water requires an urgent

and fundamental reset and there is a very short and closing

window in which a market-led solution can succeed," they said in

a statement, adding that discussions with the regulator Ofwat

and the government would be advanced in the coming weeks.

They are being advised by corporate troubleshooter Mike

McTighe, who is a potential candidate for chairman if the

proposal succeeds, according to a source close to the creditors.

Thames Water in March agreed to postpone a challenge to the

regulator's decision on how much it could increase customers'

bills while it explored the potential equity raise. That

deferral is set to expire next month.

A spokesperson for Thames Water declined to comment on the

creditors' statement. It said on Tuesday, when announcing that

KKR had walked away, that it would "progress discussions on the

senior creditors' plan with Ofwat and other stakeholders".

($1 = 0.7389 pounds)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Russia's car market faces bleak 2026 as scrappage fees drive prices up
Russia's car market faces bleak 2026 as scrappage fees drive prices up
Nov 25, 2025
(Reuters) -Russia's depressed car market has shown weak signs of recovery as 2025 draws to an end, but is set to hit near-record lows early next year as higher scrappage fees drive up prices, dealers and experts say. Far from signalling a genuine rebound, a jump in sales of new cars in October reflects a rush by buyers to complete...
RingCentral Insider Sold Shares Worth $2,007,427, According to a Recent SEC Filing
RingCentral Insider Sold Shares Worth $2,007,427, According to a Recent SEC Filing
Nov 25, 2025
03:42 AM EST, 11/25/2025 (MT Newswires) -- Vladimir Shmunis, Director, Chief Executive Officer and Chairman, on November 20, 2025, sold 73,862 shares in RingCentral ( RNG ) for $2,007,427. Following the Form 4 filing with the SEC, Shmunis has control over a total of 262,240 Class A common shares of the company, with 262,240 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1384905/000158664725000004/xslF345X05/form4-11252025_121133.xml...
Arcutis Biotherapeutics Insider Sold Shares Worth $1,517,405, According to a Recent SEC Filing
Arcutis Biotherapeutics Insider Sold Shares Worth $1,517,405, According to a Recent SEC Filing
Nov 25, 2025
03:43 AM EST, 11/25/2025 (MT Newswires) -- Todd Watanabe, Director, President and Chief Executive Officer, on November 21, 2025, sold 50,000 shares in Arcutis Biotherapeutics ( ARQT ) for $1,517,405. Following the Form 4 filing with the SEC, Watanabe has control over a total of 973,671 common shares of the company, with 740,537 shares held directly and 233,134 controlled indirectly....
BridgeBio Pharma Insider Sold Shares Worth $1,722,224, According to a Recent SEC Filing
BridgeBio Pharma Insider Sold Shares Worth $1,722,224, According to a Recent SEC Filing
Nov 25, 2025
03:43 AM EST, 11/25/2025 (MT Newswires) -- Neil Kumar, Director, Chief Executive Officer, on November 20, 2025, sold 26,156 shares in BridgeBio Pharma ( BBIO ) for $1,722,224. Following the Form 4 filing with the SEC, Kumar has control over a total of 5,622,909 common shares of the company, with 228,776 shares held directly and 5,394,133 controlled indirectly. SEC Filing:...
Copyright 2023-2026 - www.financetom.com All Rights Reserved